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and then compared using the DeLong 
method.
 
RESULTS
 
• Both tools were confirmed to be superior 
to prostate-specific antigen alone. Moreover, 
the SWOP-PRI (77.9%) displays a 7.96% 
increase in the predictive accuracy compared 
to the PCPT-CRC (69.9%) in a statistically 
significant fashion (
 
P
 
 
 
=
 
 0.002).
 
CONCLUSIONS
 
• The results obtained in the present study 
confirm the utility of nomograms with 
respect to biopsy outcome prediction 
in patients with suspicion of prostate 
cancer.
• In the current sample of patients, the 
European-based nomogram appears to be 
more accurate than the North American 
nonogram, which lacks information 
regarding prostate volume and prostatic 
ultrasonographic lesions.
• To our knowledge, this is the first study to 
compare the accuracy of these popular risk 
calculators in a specific population.
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OBJECTIVE
 
• To compare the diagnostic accuracy of 
two previously validated prostate cancer risk 
predictors on biopsy.
 
PATIENTS AND METHODS
 
• In total, 390 consecutive patients 
submitted to 10-core systematic transrectal 
prostate biopsy at our institution were 
included in this retrospective study.
• External validation of a European 
(European Randomized Study of Screening 
for Prostate Cancer derived Prostate Risk 
Indicator; SWOP-PRI) and a North American 
(Prostate Cancer Prevention Trial Cancer Risk 
Calculator; PCPT-CRC) nomogram was 
performed.
• The predictive accuracy of these online 
available nomograms was calculated based 
on the area under the curve derived from 
receiver–operator characteristic curves 
 
INTRODUCTION
 
In recent years, several nomograms have 
become available to the clinician, assisting in 
the risk stratification of prostate cancer (PCa) 
at needle biopsy [1–5]. On the basis of data 
obtained from large populations, these tools 
were developed for application in the daily 
clinical practice. However, and despite having 
shown a better predictive accuracy compared 
to PSA alone [6], the use of nomograms in the 
decision to perform prostate biopsy is not yet 
a standard practice [7].
On the other hand, different variables are 
considered in the various nomograms that 
may contribute to their individual predictive 
accuracy. In addition to increased PSA, several 
positive predictors of PCa were identified, 
including a suspicious DRE and TRUS as well 
as a positive family history, whereas an 
increased prostate volume was considered a 
negative predictor [8]. Moreover, the accuracy 
of such tools may differ according to the 
characteristics of the target population [9,10].
We considered it of interest to perform an 
external validation and compare the 
diagnostic accuracy of two popular online 
available risk calculators in a specific 
population: the European Randomized Study 
of Screening for Prostate Cancer derived 
Prostate Risk Indicator (SWOP-PRI) [1] and 
the Prostate Cancer Prevention Trial derived 
Cancer Risk Calculator (PCPT-CRC) [2].
 
PATIENTS AND METHODS
 
PATIENT POPULATION
Retrospective analysis of data from 
consecutive patients submitted to 10-core 
systematic TRUS-guided prostate biopsy at 
our institution between January 2007 and 
August 2009 was performed. Patients were 
referred to biopsy as a result of either a 
suspicious DRE and/or elevated PSA. Analysis 
targeted subjects with a PSA level 
 
<
 
50 ng/mL.
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What’s known on the subject? and What does the study add?
 
In recent years, several nomograms were developed in an effort to decrease the number 
of unnecessary prostate biopsies. The European SWOP-PRI and the North American PCPT 
are among the most popular. However, evidence on the relative predictive accuracy is 
lacking.
A head-to-head comparison on the diagnostic accuracy of two previously validated 
prostate cancer risk predictors on biopsy confirmed the superiority of these tools over PSA 
alone. Moreover, in the studied population, the European SWOP-PRI proved to be more 
accurate than the North American PCPT-CRC.
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TRUS-GUIDED PROSTATE BIOPSY
TRUS-guided prostate biopsy was performed 
using a 7-MHz probe (Prosound SSD-35005v, 
Aloka co. Ltd., Tokyo, Japan). An automatic 
biopsy gun (Porgés Laboratories, Le Plessis 
Robinson, France) with a 18-gauge needle 
(Coloplast Corporate, Humlebaek, Denmark) 
was used to obtain 10-core fragments.
RISK CALCULATORS
The European SWOP-PRI was designed based 
on data obtained from 6288 Dutch males, 
mostly Caucasian, participating in a study on 
the viability of a population-based screening 
and its effect on mortality [1]. On the other 
hand, the North-American PCPT-CRC was 
based on data obtained from 5519 males from 
the placebo group of the study evaluating the 
possible preventive effect of finasteride in PCa 
development [2]. In both populations, sextant 
biopsies were performed.
To obtain risk estimates, predictor variables 
necessary for each tool were gathered. 
Predictor variables considered for the SWOP-
PRI nomogram included abnormalities on 
DRE, serum PSA, previous negative biopsy, 
hypoechogenic lesions on TRUS and prostatic 
volume determined by ultrasonography. 
All these parameters have independent 
value in predicting biopsy outcome [7]. On 
the other hand, to obtain the risk of the 
PCPT-CRC nomogram, in addition to the 
former three predictor variables included 
for the SWOP-PRI, a family history of PCa 
was also considered. The formula for the 
latter is:
STATISTICAL ANALYSIS
Predictive variables were compared based 
on the biopsy outcome, either using a 
 
t
 
-test 
or chi-squared. Next, an external validation 
of SWOP-PRI and PCPT-CRC was performed. 
The predictive accuracy of both tools was 
assessed by analysis of the area under the 
receiver–operator characteristic (ROC) 
curve. The statistical significance of the 
difference between the areas under the ROC 
curves was analyzed using the DeLong 
method [11].
All statistical tests were performed with the 
use of the MedCalc for Windows, version 
11.2.1 (MedCalc Software, Mariakerke, 
Belgium). 
 
P
 
 
 
<
 
 0.05 (two-tailed) was 
considered statistically significant.
 
RESULTS
 
The characteristics of the study population 
are shown in Table 1. Among the 390 patients 
included in the analysis, 121 (31.0%) had 
history of a previous negative biopsy and 155 
(39.7%) were diagnosed with PCa. Age, PSA, 
DRE, prostate volume and TRUS findings were 
all significant predictors of PCa.
Table 2 displays the rate of PCa detection 
according to calculated risk for each 
1 1 1 7968
0 8488 0 2693
0 9054 0 4483
1 0
+ −( )[ ] = − +
× ( ) + ×
+ × − ×
= =( )
exp , .
. log .
. .
,
PCA beingPCA
PSA Familiar
history DRE
Previous biopsy yes no
 
TABLE 1 
 
Characteristics of the patient population submitted to prostate biopsy
 
Variable
 
n
 
Cancer No malignancy
 
P
 
Number of patients (%) 390 (100) 155 (39.7) 235 (60.3)
Age (years)
Mean 
 
±
 
 
 
SD
 
69.2 71.6 
 
±
 
 8.0 67.6 
 
±
 
 8.3
 
<
 
0.001
Range 44–89 44–89 44–87
PSA (ng/mL), mean 
 
±
 
 
 
SD
 
12.5 17.2 
 
±
 
 15.75 9.4 
 
±
 
 7.9
 
<
 
0.001
Suspicious DRE, 
 
n
 
 (%) 129 (35) 70 (47.0) 59 (26.0)
 
<
 
0.001
Prostate volume (mL)
Mean 
 
±
 
 
 
SD
 
65.4 52.0 
 
±
 
 28.6 73.3 
 
±
 
 33.9
 
<
 
0.001
Range 15–200 15–192 15–200
Hypoechogenic lesion 113 (37%) 53 (48%) 60 (31%) 0.001
 
Data are also presented according to biopsy outcome.
 
TABLE 2 
 
Rate of prostate cancer detection 
according to calculated risk for the European 
Randomized Study of Screening for Prostate 
Cancer derived Prostate Risk Indicator (SWOP-
PRI) and Prostate Cancer Prevention Trial 
derived Cancer Risk Calculator (PCPT-CRC) 
nomograms
 
Age (years)
Calculated risk (%)
SWOP-PRI PCPT-CRC
 
<
 
15 14.9 14.3
15–44 31.0 24.0
45–59 47.8 30.8
60–74 62.5 45.9
 
≥
 
75 87.5 76.8
 
FIG. 1. 
 
Receiver–operator characteristic curves for 
the European Randomized Study of Screening for 
Prostate Cancer derived Prostate Risk Indicator 
(SWOP-PRI) and Prostate Cancer Prevention Trial 
derived Cancer Risk Calculator (PCPT-CRC).
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TABLE 3 
 
Head-to-head comparison of the 
predictive accuracy of the European 
Randomized Study of Screening for Prostate 
Cancer derived Prostate Risk Indicator (SWOP-
PRI) and Prostate Cancer Prevention Trial 
derived Cancer Risk Calculator (PCPT-CRC) 
nonograms and PSA
 
SWOP-PRI PCPT-CRC
PCPT-CRC 0.002 –
PSA
 
<
 
0.001 0.044
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nomogram. Along with rising SWOP-PRI and 
PCPT-CRC risks, an increase in the rate of PCa 
detection is observed.
Figure 1 shows the ROC curves for both risk 
calculators. The accuracy of the SWOP-PRI 
was 77.9% (95% CI, 0.728–0.823; 
 
P
 
 
 
<
 
 0.001) 
vs 69.9% (95% CI, 0.645–0.749; 
 
P
 
 
 
<
 
 0.001) for 
the PCPT-CRC. Comparison of the difference 
between the areas under the ROC curves 
using the DeLong method revealed a 7.96% 
increased predictive accuracy for the SWOP-
PRI compared to the PCPT-CRC nomogram in 
a statistically significant fashion (
 
P
 
 
 
=
 
 0.002) 
(Table 3). Moreover, the area under the curve 
for serum PSA alone was 65.8% (95% CI, 
0.602–0.711; 
 
P
 
 
 
<
 
 0.001) and was significantly 
different from both risk calculators.
 
DISCUSSION
 
PCa risk calculators are valuable tools in the 
process of prostate biopsy decision-making. 
By incorporating several predictor variables, 
these tools have already proved to be superior 
to PSA alone, particularly in patients 
presenting several risk factors, and thus 
should be considered in the office-based 
clinical practice [6,8].
Various predictors of PCa were identified, 
namely suspicious DRE and TRUS findings and 
a positive family history [8]. Conversely, 
increased prostate volume and previous 
negative biopsy are considered to be negative 
predictors [2,8].
In the present study population, the areas 
under the curve for the SWOP-PRI and 
the PCPT-CRC were 77.9% and 69.9%, 
respectively, thus reproducing the previewed 
predictive accuracy in the original 
populations (79.0% and 70.2%, respectively) 
[1,2]. Moreover, considering the minimal 
accepted predictive accuracy of nomograms is 
70–80% [12], both risk calculators can be 
considered as adequate.
Nonetheless, in the present data set, the 
SWOP-PRI displays a superior accuracy 
compared to the PCPT-CRC. According to the 
results obtained in the present study, and in 
addition to any geographical and ethnical 
issues that need to be considered, the 
information concerning prostate volume and 
hypoechogenic lesions in ultrasonography 
appears to confer an added value to the tool 
when predicting the risk of PCa because these 
variables are not taken into account in the 
North-American model.
Despite the clinical implementation of these 
two parameters in all patients often proving 
difficult, recent data suugest that, even with a 
relatively approximate estimation of the total 
prostate volume by DRE, an adaptation of the 
SWOP-PRI performs better than PSA alone or 
in combination with DRE [13].
Furthermore, previous studies have shown a 
discrepancy with respect to accuracy 
according to the population under study, 
which, as well as for other reasons, could be 
justified by racial differences [9,10].
Both risk calculators were initially developed 
based on a sextant biopsy regimen, which is 
no longer current practice. Because the 
extended biopsy regimens that are now 
commonly applied will probably decrease the 
effect of prostate volume on PCa detection, 
an adaptation of these models is necessary 
[14]. Moreover, nomograms based on 
extended biopsy regimens have already 
shown an increased predictive accuracy 
compared to previously established models 
based on 6–10-core biopsies [15].
Nonetheless, the obvious limitations of PSA-
based tools should be considered when using 
these nomograms because the inconvenience 
of PCa over- and under-detection persists 
[16]. The poor correlation of serum PSA levels 
with PCa aggressiveness [17] appears to be at 
least partially responsible for the trend in 
over-diagnosis and subsequent over-
treatment in clinical practice [18]. On the 
other hand, previous data from the PCPT 
failed to reveal a PSA threshold with both 
high sensitivity and specificity when 
monitoring healthy men [19]. According to 
that study, to detect more than 80% of PCa 
cases, the PSA threshold would need to be 
1.1 ng/mL, which would mean submitting 
 
>
 
60% of men without cancer to biopsy. 
Furthermore, with a threshold of 2.6 ng/mL, 
only 40% of PCa cases would be detected.
Thus, the need for alternative PCa biomarkers 
has lead research, with the PCA3 test 
emerging as a strong candidate [20]. Recent 
data suggest that the use of this marker can 
decrease the number of unnecessary biopsies 
and possibly contribute to the reduction of 
over-diagnosis [21]. Evidence also shows that 
the PCA3 test may result in a preferential 
detection of higher risk cancers rather than 
indolent disease [16]. Additionally, several 
studies of genetic susceptibility to the 
development of PCa are also in progress [20].
In conclusion, despite their limitations, the 
risk indicators evaluated in the present study 
can be of added value when defining a 
starting point in patient assessment and 
should be considered in clinical practice. 
However, improvements regarding the 
selective identification of men who are 
susceptible to the development of life-
threatening disease are mandatory, and will 
hopefully contribute to the timely and proper 
management of these patients.
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